Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>Abemaciclib metabolite M18 hydrochloride

Abemaciclib metabolite M18 hydrochloride (Synonyms: LSN3106729 hydrochloride)

Catalog No.GC63728

Le chlorhydrate du métabolite M18 (LSN3106729) d'Abemaciclib, le métabolite de l'Abemaciclib, est un inhibiteur de CDK avec une activité antitumorale. Le chlorhydrate du métabolite M18 de l'abémaciclib et un ligand CRBN ont été utilisés pour concevoir le dégradeur PROTAC CDK4/6.

Products are for research use only. Not for human use. We do not sell to patients.

Abemaciclib metabolite M18 hydrochloride Chemical Structure

Taille Prix Stock Qté
10mM (in 1mL DMSO)
368,00 $US
En stock
5 mg
315,00 $US
En stock
10 mg
495,00 $US
En stock
25 mg
891,00 $US
En stock
50 mg
1 485,00 $US
En stock
100 mg
2 025,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1].

[1]. Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.
[2]. Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1.

Avis

Review for Abemaciclib metabolite M18 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Abemaciclib metabolite M18 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.